Amrize (AMRZ) marketing chief buys 1,500 company shares

Amrize Ltd (AMRZ) reported that its Chief Marketing & Corporate Affairs Officer, Forrest Nollaig, purchased 1,500 shares at $44.15 each on 2026-08-25, increasing his direct stake to 21,639 shares. The transaction was conducted in an open market or private deal.

Original reporting
Published Aug 25, 2026, 7:54 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 8:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$AMRZ
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

Low
01

Timing

reported on 2026-08-25

Relevance 4/10Novelty 4/10Timing: reported on 2026-08-25

Related articles

$AMRZMedAI 8/10

Amrize (AMRZ) Q2 2026 Earnings Call Transcript

Amrize AG (AMRZ) reported Q2 2026 revenue of $3.49B, up 8.6%, and net income of $476M, up 14.4%, with adjusted EBITDA of $986M. Management raised fiscal 2026 revenue guidance to $12.5B-$12.7B but revised adjusted EBITDA to $3.1B-$3.2B due to oil-driven cost inflation. The company cited data center and infrastructure demand.

$AMRZMedAI 8/10

Amrize Q2 EPS misses $0.94 estimate as costs weigh on margins

Amrize (NYSE: AMRZ) reported Q2 2026 adjusted EPS of $0.88, below the $0.94 consensus estimate. Revenue rose 8.51% to $3.494 billion, beating the $3.365 billion expectation. Net income increased 14.4% to $476 million. The company raised FY2026 revenue guidance to $12.5B-$12.7B but lowered adjusted EBITDA guidance to $3.1B-$3.2B due to cost inflation.

$AMRZMed

RBC Downgrades Amrize After A Rare Q2 Miss

RBC downgraded Amrize after a rare Q2 miss and reduced guidance, citing a timing mismatch between input-cost increases and the full pass-through of surcharges and price hikes. RBC cut 2026-2028 EBITDA estimates by 4%, 6%, and 7% and EPS by 12%, 14%, and 15%, lowering its stock rating to underperform and price target to $48 from $60.